{"entity":{"id":"nct07243340","kind":"trial","name":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor","aka":[],"tldr":"A phase 1/2 trial of Herpes Virus C5252 Injection in glioma & glioblastoma, run by ImmVira Pharma Co. Ltd, now recruiting.","summary":"A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor is a phase 1/2 interventional study registered as NCT07243340 by ImmVira Pharma Co. Ltd, with 36 participants planned, started 2026-04-03 and due to reach its primary completion in 2027-12-15. Interventions recorded: Herpes Virus C5252 Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07243340","url":"https://clinicaltrials.gov/study/NCT07243340"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07243340","phase":"1/2","setting":"A Phase I/IIa Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Herpes Virus C5252 Injection in Patients With Intracranial Tumor","sponsor":"ImmVira Pharma Co. Ltd","enrolled":36,"outcomes":[]},"route":"/trials/nct07243340/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"company":[{"id":"immvira-pharma","kind":"company","name":"ImmVira Pharma","route":"/companies/immvira-pharma/"}]}}